Endovascular treatmenT for Acute Ischemic Stroke in China

Stroke Clinical Trial

— DETECT-China  

Official title:

Endovascular treatmenT for Acute Ischemic Stroke in China: a Retrospective, National, Multi-center, Registry Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04752735
• Other study ID #: y (2021)013
• Status: Completed
• Start date: March 22, 2021
• Est. completion date: February 8, 2023

Study information

• Verified date: February 2023
• Source: General Hospital of Shenyang Military Region
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a retrospective real world registry study, aiming to explore the effectiveness and safety of endovascular treatment of acute ischemic stroke in a Chinese population.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1000
• Est. completion date: February 8, 2023
• Est. primary completion date: February 8, 2023
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age: = 18;

• Ischemic stroke confirmed by head CT or MRI;

• Patients receiving endovascular treatment;

• First ever stroke or mRS=2 after previous disease;

• Complete and clear pre- and post-operative DSA images are available

Exclusion Criteria:

• Imaging data not qualified for evaluation;

• Absence of important clinical data;

• The first 50 patients receiving endovascular treatment in a single centerr.

Related Conditions & MeSH terms

• Endovascular Treatment
• Ischemic Stroke
• Stroke

Intervention

Other:
• endovascular treatment
all enrolled patients must receive endovascular treatment.

Locations

Country	Name	City	State
China	Department of Neurology, General Hospital of Northern Theater Command	Shenyang

Sponsors (1)

Lead Sponsor	Collaborator
General Hospital of Shenyang Military Region

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of patients with modified Rankin Score (mRS) 0 to 2	the minimum and maximum values of mRS are 0 and 6, respectively; higher mRS mean a worse outcome	Day 90
Secondary	Changes in National Institute of Health stroke scale (NIHSS)	the minimum and maximum values of NIHSS are 0 and 42, respectively; higher NIHSS mean a worse outcome	Day 2, 7, 14
Secondary	Proportion of patients with modified Rankin Score 0 to 2	Proportion of patients with modified Rankin Score 0 to 2	Day180, 360
Secondary	Distribution of modified Rankin Score	Distribution of modified Rankin Score after treatment	Day 90, 180, 360
Secondary	Proportion of symptomatic intracranial hemorrhage (sICH)	sICH was defined as 4 or more increase in NIHSS caused by hemorrhage	48 hours
Secondary	Proportion of intraparenchymal hemorrhage (PH1 and PH2)	Proportion of intraparenchymal hemorrhage (PH1 and PH2) after treatment	48 hours
Secondary	Proportion of death	death due to any cause	Day 7
Secondary	Changes in cerebral edema	edema is determined by middle shift.	48 hours, 7 days